Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer

Vista sencilla de ítem
dc.citation.titleIndian Journal of Canceres
dc.citation.volume50es
dc.creatorPerroud, Herman A
dc.creatorRico, María José
dc.creatorAlasino, Carlos María
dc.creatorPezzotto, Stella Maris
dc.creatorRozados, Viviana R.
dc.creatorScharovsky, O. Graciela
dc.date.accessioned2018-07-26T15:41:45Z
dc.date.available2018-07-26T15:41:45Z
dc.date.issued2013-08-27
dc.descriptionBackground: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of response have been found yet that allow patient selection for treatment. AIM: To investigate the potential role as biomarkers of pro- and antiangiogenic parameters and evaluate their response in ABCP receiving metronomic Cy 50 mg p.o./day + Cel 400 mg p.o./day. Materials and Methods: Serum levels of vascular endothelial growth factor-C (VEGF-C), soluble VEGF receptors 2 and 3 (sVEGFR-2, sVEGFR-3), were measured at different time points in 13/15 patients included in a phase II trial of MCT with Cy+Cel. Results: Serum levels of sVEGFR-2 and sVEGFR-3 increased significantly during treatment (P = 0.0392; P = 0.0066, respectively). VEGF-C showed no significant modifications. Previous determinations of VEGF and TSP-1 in the same patients were utilized. VEGF/sVEGFR-2, VEGF/TSP-1, and VEGF-C/sVEGFR-3 ratios decreased significantly along the treatment (P = 0.0092; P = 0.0072; P = 0.0141, respectively). Nonsignificant variations were observed for VEGF-C/sVEGFR-2 ratio. Baseline values of VEGF/sVEGFR-2 and VEGF/TSP-1 ratios were associated with time to progression (TTP) (P = 0.0407; P = 0.0394, respectively) meanwhile baseline VEGF was marginally significant (P = 0.0716). Patients with values lower than the 50 th percentile for both ratios showed longer TTP. Conclusions: We have identified the baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios as potential biomarkers of response in ABCP treated metronomically with Cy+Cel. This finding warrants its confirmation in a higher number of patients.es
dc.description.filFil: Perroud, Herman A. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Rico, María José. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Alasino, Carlos María. Institute of Oncology of Rosario; Rosario; Argentina.es
dc.description.filFil: Pezzotto, Stella Maris. Research Council of the National University of Rosario (CIUNR); Rosario; Argentina.es
dc.description.filFil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina.es
dc.description.filFil: Scharovsky, Graciela Olga. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina.es
dc.formatapplication/pdf
dc.format.extent115-121es
dc.identifier.issn0019-509Xes
dc.identifier.urihttp://hdl.handle.net/2133/11554
dc.language.isoenges
dc.publisherIndian Cancer Society and Indian Society of Oncologyes
dc.relation.publisherversionhttp://www.indianjcancer.com/article.asp?issn=0019-509X;year=2013;volume=50;issue=2;spage=115;epage=121;aulast=Perroudes
dc.relation.publisherversion10.4103/0019-509X.117031es
dc.rightsopenAccesses
dc.rights.holder© 2007 - 2018 Indian Journal of Canceres
dc.rights.texthttps://creativecommons.org/licenses/by-nc-sa/4.0/es
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectBiomarkerses
dc.subjectCelecoxib es
dc.subjectCyclophosphamidees
dc.subjectmetronomic chemotherapyes
dc.titleAssociation between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast canceres
dc.typearticle
dc.typeartículo
dc.typepublishedVersion
dc.type.collectionarticulo
dc.type.versionpublishedVersiones

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Perroud et al IJC 2013.pdf
Tamaño:
687.23 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.59 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

CIUNR - Ciencias Naturales - Artículos de Revista
FCM - Instituto de Genética Experimental - Artículos